您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Nateglinide-d5
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nateglinide-d5
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nateglinide-d5图片
CAS NO:1227666-13-8
包装:1mg
市场价:2948元

产品介绍
那格列奈-d5 是氘标记的那格列奈。
Cas No.1227666-13-8
别名那格列奈-D5,A4166 D5; Senaglinide D5
Canonical SMILESCC(C)[C@H]1CC[C@H](C(N[C@H](CC2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])C(O)=O)=O)CC1
分子式C19H22D5NO3
分子量322.5
溶解度Chloroform: slightly soluble,Methanol: slightly soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Nateglinide-d5is intended for use as an internal standard for the quantification of nateglinide by GC- or LC-MS. Nateglinide is a hypoglycemic agent.1,2,3It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 μM.1Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic β cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine . Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide . Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice.2It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin .3Formulations containing nateglinide have been used in the treatment of type 2 diabetes.

1.Fujitani, S., Ikenoue, T., Akiyoshi, M., et al.Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreasMetabolism45(2)184-189(1996) 2.Shinkai, H., Toi, K., Kumashiro, I., et al.N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agentsJ. Med. Chem.31(11)2092-2097(1988) 3.Sato, Y., Nishikawa, M., Shinkai, H., et al.Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animalsDiabetes Res. Clin. Pract.12(1)53-59(1991)